Literature DB >> 15582127

Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease.

Paul Angulo1, Laura M Alba, Lydia M Petrovic, Leon A Adams, Keith D Lindor, Michael D Jensen.   

Abstract

BACKGROUND/AIMS: Data from animal models of fibrosis and fatty liver suggest that leptin may mediate the profibrogenic responses in the liver, but the association of leptin and liver fibrosis in human nonalcoholic fatty liver disease (NAFLD) remains undefined. We aimed at determining the relation between leptin and liver fibrosis in human NAFLD.
METHODS: Human plasma leptin and several indicators of insulin resistance were measured in 88 NAFLD patients and matched controls.
RESULTS: Leptin levels were significantly greater in patients with more advanced fibrosis (P = 0.005). By multivariate analysis, the significant association between leptin and fibrosis was abolished (adjusted P = 0.3) when controlling for confounders including age, gender, BMI, diabetes and insulin resistance. Only age (adjusted P = 0.006) and insulin sensitivity (adjusted P = 0.04) correlated significantly with fibrosis stage. A second liver biopsy was performed in 39 out of the 88 patients at 27.9 +/- 16 months. Leptin levels were not significantly different between patients who had fibrosis progression (n = 10) and those who did not (n = 29).
CONCLUSIONS: In human NAFLD, no relationship between leptin levels and fibrosis stage was demonstrated. The correlation of leptin and fibrosis severity seems to be an indicator of the factors that determine leptin production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15582127     DOI: 10.1016/j.jhep.2004.08.020

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  64 in total

1.  Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.

Authors:  Michael Charlton; Anuradha Krishnan; Kimberly Viker; Schuyler Sanderson; Sophie Cazanave; Andrea McConico; Howard Masuoko; Gregory Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

Review 2.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

Review 3.  Inflammation and fibrogenesis in steatohepatitis.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2012-02-07       Impact factor: 7.527

4.  The efficacy of adipokines and indices of metabolic syndrome as predictors of severe obesity-related hepatic steatosis.

Authors:  Nahum Méndez-Sánchez; Norberto C Chávez-Tapia; Roberto Medina-Santillán; Antonio R Villa; Karla Sánchez-Lara; Guadalupe Ponciano-Rodríguez; Martha H Ramos; Misael Uribe
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

5.  Current and novel therapies for the treatment of nonalcoholic steatohepatitis.

Authors:  David van der Poorten; Jacob George
Journal:  Hepatol Int       Date:  2007-07-26       Impact factor: 6.047

6.  Effects of long-term cranberry supplementation on endocrine pancreas in aging rats.

Authors:  Min Zhu; Jingping Hu; Evelyn Perez; Dawn Phillips; Wook Kim; Reza Ghaedian; Joshua K Napora; Sige Zou
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-07-18       Impact factor: 6.053

Review 7.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 8.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

Review 9.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

10.  Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD).

Authors:  Joanna Raszeja-Wyszomirska; Barbara Szymanik; Małgorzata Ławniczak; Maciej Kajor; Alina Chwist; Piotr Milkiewicz; Marek Hartleb
Journal:  BMC Gastroenterol       Date:  2010-06-28       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.